A new Mirena lawsuit has been filed by a woman in Indiana whose unborn baby was shown to have birth defects after the IUD allegedly broke into several pieces within her body, court records show.
According to a November 12th report, the Plaintiff says she was first implanted with the birth control device in March 2011, when she was 19 years old. At the time, she had already given birth to one child, which would make her a good candidate for the IUD, according to a recommendation listed on the website of Bayer Healthcare Pharmaceuticals. She sought to have the device removed, her lawsuit alleges, which was when her surgeon found the t-shaped implant had broken apart into several pieces, and released an uncontrolled amount of hormones into her body.
In an ultrasound report issued later, the Plaintiff’s baby was shown to have two serious birth defects, including anencephaly, a neural tube defect in which the infant is born without parts of the skull and brain, and acalvaria. These birth defects, as well as her now-inability to conceive, were caused by Mirena complications stemming from the IUD, according to her lawsuit.
The Indiana woman says her troubles are still not over, however. Her lawsuit states that she continues to suffer “dysfunctional uterine bleeding, intermenstrual bleeding, irregular menstruation, abdominal pain” and other complications even after undergoing Mirena removal surgery.
Mirena Lawsuits Continue to Mount
Although a Mirena recall has not been announced, more and more women in the U.S. are coming forward to file lawsuits. According to court documents, at least 211 cases alleging spontaneous migration of the IUD and uterine perforations, among other complications associated with the device are pending in a federal litigation underway in the U.S. District Court, Southern District of New York. In a multicounty proceeding established in New Jersey’s Bergen County Superior Court, at least 219 lawsuits have been filed.
Similar actions against Bayer allege the company’s failure to provide adequate warnings related to the potential for its product, which is used by approximately 2 million women in the U.S., to cause patient injuries.